Related Experiment Videos
Itraconazole: a single-day oral treatment for acute vulvovaginal candidosis
1Department of Gynaecology, Clinique Chirurgicale de Braine-L'Alleud, Belgium.
Abstract:
Itraconazole is an oral broad-spectrum antifungal agent with a propensity to leave the plasma and achieve high and persistent levels in tissues where fungi reside. Indeed, the highly lipophilic character of itraconazole results in a favourable tissue:blood ratio: most tissue concentrations exceed by far concentrations in the blood. Itraconazole has a depot effect in the skin and mucous membranes without leaking back into the plasma. In addition, the high lipophilicity and the specific molecular shape result in the ability to easily penetrate Candida cell membranes and in a high selectivity for Candida cytochrome P450. At therapeutic doses there is no known interference with human enzyme systems. This promising pharmacological profile has been challenged in extensive clinical trials. The feasibility of one-day therapy was assessed in a clinical study in which three different dosage regimens were compared in a total of 552 patients with acute vulvovaginal candidosis: 200 mg twice daily for one day; 200 mg once daily for two days; and 200 mg once daily for three days. A total dose of 400 mg of itraconazole given in one single day cured 80% of patients (defined as mycologically negative) one month after the end of treatment. The results indicate that the difference in the length of therapy (one, two or three days) plays no statistically significant role in determining the final cure rate of itraconazole in acute vulvovaginal candidosis. Subsequent pharmacokinetic analysis indicated that therapeutic concentrations of itraconazole persist in the vaginal wall for at least three days after discontinuation of therapy, suggesting that one-day therapy would be appropriate.
Insights
A single day of oral itraconazole treatment effectively cures acute vulvovaginal candidosis. This antifungal medication achieves high tissue concentrations, making short-duration therapy feasible and efficient for patients.
Area of Science:
- Pharmacology
- Mycology
- Clinical Medicine
Background:
- Itraconazole is a broad-spectrum oral antifungal agent.
- It exhibits high lipophilicity, leading to favorable tissue distribution and persistent levels.
- The drug demonstrates high selectivity for Candida cytochrome P450 with no known interference with human enzymes.
Purpose of the Study:
- To assess the feasibility of one-day itraconazole therapy for acute vulvovaginal candidosis.
- To compare different dosage regimens of itraconazole in terms of efficacy and cure rates.
- To evaluate the pharmacokinetic profile of itraconazole in vaginal tissues.
Main Methods:
- A clinical study involving 552 patients with acute vulvovaginal candidosis.
- Comparison of three dosage regimens: 200 mg twice daily for one day, 200 mg once daily for two days, and 200 mg once daily for three days.
- Mycological assessment one month post-treatment to determine cure rates.
Main Results:
- A total dose of 400 mg itraconazole administered in one day achieved an 80% cure rate.
- No statistically significant difference in cure rates was observed between one, two, or three-day treatment durations.
- Pharmacokinetic analysis revealed persistent therapeutic itraconazole concentrations in the vaginal wall for at least three days post-therapy.
Conclusions:
- One-day itraconazole therapy is an appropriate and effective treatment for acute vulvovaginal candidosis.
- The duration of therapy (one, two, or three days) does not significantly impact the final cure rate.
- The sustained presence of itraconazole in vaginal tissues supports the efficacy of short-duration treatment regimens.